A fluid connector, including a fluid path portion having an integral cannula extending in a first direction from a interior surface, and a latching portion secured to the fluid path portion and having a pair of displaceable arms. Each arm includes a connector latch disposed at a first cantilevered end of the arm, and an activation lever disposed at an opposite cantilevered end of the arm and extending in a second direction, not parallel to the first direction. A portion of the activation lever includes a first lateral tactile feature aligned substantially parallel to the first direction to prevent forward slippage of the fluid connector from a user's grasp in the second direction, and a portion of the activation lever includes a lateral tactile feature aligned substantially parallel to the second direction to prevent slippage of the fluid connector from a user's grasp in the first direction.

According to aspects disclosed herein, an infusion lead assembly may include a housing including a needle receptacle, a housing lumen, a pin receptacle, and a housing conductive trace; a connector including an connector needle, an internal lumen, a metal pin, and a connector conductive trace, and an infusion lead body including an infusion lumen, an exit port, an internal wire, and a distal electrode. The infusion lead assembly may form an electrical path to transmit electrical signals across the connector conductive trace, the metal pin, the housing conductive trace, the internal wire, and the distal electrode. The infusion lead assembly may form a fluid path to transmit fluid across the internal lumen, the connector needle, the infusion lumen, and the exit port.

The present disclosure relates to methods, devices, kits and systems for enhancing the efficacy and longevity of denervation procedures.

A method of treating a subject which may be a human suffering from epilepsy which may be a form of epilepsy resistant to treatment and particular patients which are resistant to treatment with oral medication. The method involves positioning a catheter device in the subject's brain and infusing a liquid formulation of a drug into a portion of the subject's brain through an infusion lumen at a rate of 5, 4, 3, 2, or 1 ml or less per day ±50%. The infusion may be constant and corrected by aspirating fluid from the patient's brain and testing the aspirated fluid for drug concentration. The rate of infusion by the formulation and the concentration of drug may be adjusted based on patient responsiveness.

A number of variations may include a sterile kit that may include a tray constructed and arranged to hold the necessary items to access an Ommaya reservoir and the tray may define a plurality of other resources or indentations constructed and arranged to seat, hold, or house additional components of the sterile kit. The sterile kit may additionally include a paper towel, a fenestrated drape, a plurality of sponge applicators, at least one pouch of povidone-iodine, at least one retractable winged butterfly needle, at least one luer lock syringe, a 3-way stopcock, a plurality of collection vials with tops which may be screwed on to prevent the contents thereof from leaking or escaping, sterile pads, bandages including adhesive bandages, and other components.

Apparatus and methods for controlled arterial/venous access are provided. The apparatus and methods may include a lumen anastomosed to a bodily lumen. A lumen clamping means may utilize a clamp manipulator to effectively seal the tubing, and the manipulator may be operated by two fingers. A needle receptor may be utilized, and the receptor may utilize a compressible member to seal tightly against a needle inserted from outside the body, in order ensure secure placement into a channel. The channel may be in liquid communication with the tubing. The manipulator and the needle receptor may be palpable from outside the body.

Disclosed herein are vascular access systems and methods thereof. For example, a vascular access system includes a port configured for subdermal implantation and a single-use access device. The port can include a port hub and a catheter tube. The port hub can include an access funnel and a septum defining a pair of port-hub lumens. The catheter tube can include a septum defining a pair of catheter-tube lumens fluidly coupled to the pair of port-hub lumens. The access device can include a bifurcated hub and a pair of cannulas. The pair of cannulas defines a pair of cannula lumens coupled to a pair of access device-hub lumens of the bifurcated hub. The pair of cannulas can be configured to simultaneously insert into the access funnel and couple the pair of cannula lumens to the pair of catheter-tube lumens when the pair of cannulas is fully seated in the port hub.

In some examples, a catheter assembly includes a catheter including an elongated catheter body defining a lumen, a first cuff and a second cuff. The first cuff includes a first cuff body comprising a material configured to promote epidermal tissue growth around or within the first cuff and an adhesive configured to adhere the first cuff body to an outer surface of the elongated catheter body at a first cuff position selectable by a user. The second cuff includes a second cuff body comprising the material configured to promote epidermal tissue growth around or within the second cuff body and an adhesive configured to adhere the second cuff body to the outer surface of the elongated catheter body at a second cuff position selectable by the user. A distance between the first and second cuff positions is customizable by the user based on a patient.

Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure is positioned within a region of the housing away from the access portion opening into a reservoir chamber extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover is coupled to at least an upper surface of the proximal retention structure.

A system for treating heart disease, such as pulmonary hypertension or right heart failure, including an implantable component and external components for monitoring the implantable component is provided. The implantable component may include a compliant member, e.g., balloon, coupled to a reservoir via a conduit. Preferably, the compliant member is adapted to be implanted in a pulmonary artery and the reservoir is adapted to be implanted subcutaneously. The external components may include a clinical controller component, monitoring software configured to run a clinician's computer, a patient monitoring device, and a mobile application configured to run on a patient's mobile device.